A Phase 2 interventional study of IgPro20 and IgPro10 in Diffuse Cutaneous Systemic Sclerosis, sponsored by CSL Behring. Completed at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Scleroderma, Diffuse with a site in Poland — 4 open to participants now, 10 under way, 2 of them phase 3. Scleroderma, Diffuse · Poland.
Among the 19 studies in Scleroderma, Diffuse with a site in Poland, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 in phase 2, and was the 6th registered.
310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.
Browse Scleroderma, Diffuse studies →4 of the 19 studies in Scleroderma, Diffuse with a site in Poland are open now. Recruiting first, the newest first:
Mediar Therapeutics · Sites in Poland, United States, Australia and 7 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Poland, United States, Australia and 7 more countries
Ages 18+
Artiva Biotherapeutics, Inc. · Sites in Poland, United States, Brazil and 8 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Poland, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 38 across 227 interventional studies indexed under Scleroderma, Diffuse.
Median enrollment 108 across the 18 interventional studies, 272 across the 1 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 2 studies filed under Scleroderma, Diffuse — fewer than ten, so there is no comparison to draw.
3 of the studies in Scleroderma, Diffuse with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
| NCT06470048Novartis PharmaceuticalsA Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Scleroderma, Diffuse with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, randomized, open-label, crossover study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in participants with diffuse cutaneous systemic sclerosis (dcSSc). The pharmacokinetic study aims to evaluate the relative bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10, respectively, in participants with dcSSc. Safety, tolerability, and pharmacokinetics of IgPro10 will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received IgPro20 of a total dose of 0.5 grams per kilogram (g/kg) over 2 sessions per week as a subcutaneous (SC) injection for up to 16 weeks in Treatment Period 1 followed by IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an intravenous (IV) infusion for up to 16 weeks in Treatment Period 2.
Biological: IgPro20 · Biological: IgPro10
Participants received IgPro10 of a total dose of 2 g/kg over 2 to 5 sessions on consecutive days every 4 weeks as an IV infusion for up to 16 weeks in Treatment Period 1 followed by IgPro20 of a total dose of 0.5 g/kg over 2 sessions per week as a SC injection for up to 16 weeks in Treatment Period 2.
Biological: IgPro20 · Biological: IgPro10
Number of Participants With at Least One Adverse Event (AE) for IgPro20
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Percentage of Participants With at Least One AE for IgPro20
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) for IgPro20
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Percentage of Participants With at Least One TEAE for IgPro20
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Number of Participants With at Least One Serious Adverse Event (SAE) for IgPro20
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Percentage of Participants With at Least One SAE for IgPro20
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Number of Participants With at Least One Adverse Event of Special Interest (AESI) for IgPro20
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
Time frame: From first dose of study drug through last follow-up visit (up to 36 weeks)
Percentage of Participants With at Least One AESI for IgPro20
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Percentage of Participants With AEs Categorized as ISRs for IgPro20
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Rate of ISRs Per Infusion for IgPro20
ISR rate per infusion = total number of ISRs across all participants while on IgPro20 / total number of IgPro20 Infusions across all participants. ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions NEC', 'Infusion site reactions', or 'Injection site reactions'
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Time to Onset of ISRs for IgPro20
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Time to onset of ISR since the start of the treatment period was reported.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Duration of ISRs for IgPro20
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro20
Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Changes in Vital Signs for IgPro20
Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20
Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20
PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Relative Bioavailability (%F) of IgPro20
Relative bioavailability was calculated using Mixed Model Repeated Measures on Log-transformed Dose-normalized area under the curve to the end of the dosing period \[AUC0-tau\] following administration of the first dose of IgPro20 in the last week of dosing for Sequence A and / or Sequence B. Relative Bioavailability= (AUCtau IgPro20 (SC)/dose of IgPro20 (SC) / (AUCtau of IgPro10 (IV)/dose of IgPro10 (IV)).
Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro20
Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20
Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Maximum Plasma Drug Concentration (Cmax) for IgPro20
Time frame: Seq A-(Pre-injection [inj] at Weeks [Wks] 1,5,9,13,14; 24,48,72,96,168 hours [hrs] post 1st inj at Wk 14; 240 hrs post 1st inj at Wk 15), Seq B-(Pre-inj at Wks 17,21,25,29,30; 24,48,72,96,168 hrs post 1st inj at Wk 30; 240 hrs post 1st inj at Wk 31)
Minimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence A
Time frame: Pre-injection at Weeks 5, 9, 13, and 14
Minimum Plasma Drug Concentration (Ctrough) for IgPro20 in Sequence B
Time frame: Pre-injection at Weeks 21, 25, 29, and 30
Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10
Time frame: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16
Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10
Time frame: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16
Maximum Plasma Drug Concentration (Cmax) for IgPro10
Time frame: Seq A and B respectively-Pre-infusion (inf) at Wks 17,21,25,29 and 1,5,9,13; 1 hour (hr) post 1st and 2nd inf, 168 hr post 1st inf at Wk 29,13; 264 and 336 hr post 1st inf at Wk 30, 14; 504 hr post 1st inf at Wk 31,15; 672 hr post 1st inf at Wk 32,16
Minimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence A
Time frame: Pre-infusion at Weeks 21, 25 and 29
Minimum Plasma Drug Concentration (Ctrough) for IgPro10 in Sequence B
Time frame: Pre-infusion at Weeks 5, 9 and 13
Number of Participants With at Least One AE for IgPro10
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Percentage of Participants With at Least One AE for IgPro10
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With at Least One TEAE for IgPro10
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Percentage of Participants With at Least One TEAE for IgPro10
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With at Least One SAE for IgPro10
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Percentage of Participants With at Least One SAE for IgPro10
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With at Least One AESI for IgPro10
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Percentage of Participants With at Least One AESI for IgPro10
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With AEs Categorized as ISRs for IgPro10
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Percentage of Participants With AEs Categorized as ISRs for IgPro10
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro10
Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Changes in Vital Signs for IgPro10
Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Abnormalities in ECG Parameters for IgPro10
Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Number of Participants With Clinically Significant Abnormalities in PFTs for IgPro10
PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Rate of ISRs Per Participant for IgPro20
Time frame: From first dose of study drug through last follow up visit (up to 36 weeks)
Participants were enrolled at study centers in Australia, Germany, Italy, Poland, and the United Kingdom from 19 September 2019 to 17 May 2022.
| Milestone | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) |
|---|---|---|
| Started | 13 | 14 |
| Completed | 12 | 13 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) |
|---|---|---|
| Started | 13 | 13 |
| Completed | 13 | 12 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With at Least One Adverse Event (AE) for IgPro20 | 9 | 9 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
| percentage of participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Percentage of Participants With at Least One AE for IgPro20 | 69.2 | 69.2 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) for IgPro20 | 9 | 9 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
| percentage of participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Percentage of Participants With at Least One TEAE for IgPro20 | 69.2 | 69.2 |
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With at Least One Serious Adverse Event (SAE) for IgPro20 | 2 | 3 |
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
| percentage of participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Percentage of Participants With at Least One SAE for IgPro20 | 15.4 | 23.1 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With at Least One Adverse Event of Special Interest (AESI) for IgPro20 | 0 | 1 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
| percentage of participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Percentage of Participants With at Least One AESI for IgPro20 | 0 | 7.7 |
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With AEs Categorized as Infusion Site Reactions (ISRs) for IgPro20 | 2 | 3 |
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
| percentage of participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Percentage of Participants With AEs Categorized as ISRs for IgPro20 | 15.4 | 23.1 |
ISR rate per infusion = total number of ISRs across all participants while on IgPro20 / total number of IgPro20 Infusions across all participants. ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions NEC', 'Infusion site reactions', or 'Injection site reactions'
| ISRs per infusion | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Rate of ISRs Per Infusion for IgPro20 | 0.0057 | 0.0360 |
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'. Time to onset of ISR since the start of the treatment period was reported.
| days | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Time to Onset of ISRs for IgPro20 | 2.0 (1 to 3) | 15.0 (1 to 64) |
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
| minutes | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Duration of ISRs for IgPro20 | 162.0 (162 to 162) | 220.0 (180 to 1170) |
Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro20 | 0 | 0 |
Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs for IgPro20 | 0 | 0 |
Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters for IgPro20 | 0 | 1 |
PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.
| Participants | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Pulmonary Function Tests (PFTs) for IgPro20 | 0 | 0 |
Relative bioavailability was calculated using Mixed Model Repeated Measures on Log-transformed Dose-normalized area under the curve to the end of the dosing period \[AUC0-tau\] following administration of the first dose of IgPro20 in the last week of dosing for Sequence A and / or Sequence B. Relative Bioavailability= (AUCtau IgPro20 (SC)/dose of IgPro20 (SC) / (AUCtau of IgPro10 (IV)/dose of IgPro10 (IV)).
| percentage bioavailability | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Relative Bioavailability (%F) of IgPro20 | 0.831 (0.7343 to 0.9396) | 0.698 (0.6235 to 0.7804) |
| hours*grams per liter (h*g/L) | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro20 | 3835.68 (3394.749 to 4333.883) | 3581.08 (3326.635 to 3854.997) |
| h*g/L | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro20 | 5361.61 (4729.962 to 6077.619) | 4898.02 (4437.732 to 5406.046) |
| g/L | Sequence A: IgPro20 | Sequence B: IgPro20 |
|---|---|---|
| Maximum Plasma Drug Concentration (Cmax) for IgPro20 | 24.237 (21.6041 to 27.1898) | 23.203 (21.7278 to 24.7782) |
| g/L | Sequence A: IgPro20 |
|---|---|
| Week 5 | 22.046 (16.69 to 63.70) |
| Week 9 | 21.950 (14.71 to 30.51) |
| Week 13 | 22.354 (16.98 to 31.36) |
| Week 14 | 21.814 (14.49 to 27.93) |
| g/L | Sequence B: IgPro20 |
|---|---|
| Week 21 | 20.427 (12.82 to 25.48) |
| Week 25 | 21.603 (16.92 to 30.49) |
| Week 29 | 21.903 (18.89 to 28.47) |
| Week 30 | 20.497 (18.15 to 23.59) |
| h*g/L | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Area Under the Concentration Curve to the End of the Dosing Period (AUC0-tau) for IgPro10 | 16942.66 (15097.493 to 19013.345) | 17672.03 (16402.479 to 19039.837) |
| h*g/L | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Area Under the Concentration Curve up to the Last Measurable Concentration (AUC0-last) for IgPro10 | 16520.48 (14742.232 to 18513.218) | 17349.72 (15917.101 to 18911.275) |
| g/L | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Maximum Plasma Drug Concentration (Cmax) for IgPro10 | 47.142 (41.2538 to 53.8713) | 44.996 (39.2110 to 51.6340) |
| g/L | Sequence A: IgPro10 |
|---|---|
| Week 21 | 16.123 (9.69 to 34.70) |
| Week 25 | 17.497 (8.80 to 54.96) |
| Week 29 | 16.838 (8.51 to 58.16) |
| g/L | Sequence B: IgPro10 |
|---|---|
| Week 5 | 17.104 (12.77 to 24.04) |
| Week 9 | 17.744 (13.92 to 23.36) |
| Week 13 | 17.113 (12.89 to 25.43) |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With at Least One AE for IgPro10 | 5 | 8 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.
| percentage of participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Percentage of Participants With at Least One AE for IgPro10 | 38.5 | 57.1 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With at Least One TEAE for IgPro10 | 5 | 8 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs are defined as AEs reported at or after the start of the first infusion in the study.
| percentage of participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Percentage of Participants With at Least One TEAE for IgPro10 | 38.5 | 57.1 |
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With at Least One SAE for IgPro10 | 1 | 1 |
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, or is a medically significant event.
| percentage of participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Percentage of Participants With at Least One SAE for IgPro10 | 7.7 | 7.1 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With at Least One AESI for IgPro10 | 0 | 0 |
AE is any untoward medical occurrence in a patient or clinical investigation participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An AESI is an AE of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor is appropriate.
| percentage of participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Percentage of Participants With at Least One AESI for IgPro10 | 0 | 0 |
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With AEs Categorized as ISRs for IgPro10 | 0 | 0 |
ISRs included all events reported within the MedDRA high-level terms 'Administration site reactions', 'Infusion site reactions', or 'Injection site reactions'.
| percentage of participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Percentage of Participants With AEs Categorized as ISRs for IgPro10 | 0 | 0 |
Abnormality criteria:Hematology-Hemoglobin:\<10 g/dL;Platelet count:\<75x10\^9/L or \>500x10\^9/L;White Blood Cell Count:\<3x10\^9/L or \>16x10\^9/L;Neutrophils:absolute \<1.5x10\^9/L,differential \<40%;Lymphocytes:absolute \<0.8x10\^9/L,differential \<10 or \>50%; Biochemistry-Bilirubin:\>1.5xupper limit of normal (ULN);Alkaline phosphatase:\>2.5xULN;Serum Glutamic-oxalacetic transaminase(SGOT), Aspartate transaminase(AST):\>3xULN;Serum glutamic-pyruvic transaminase(SGPT), Alanine transaminase(ALT):\>3xULN;Screening:AST/ALT \>3xULN and Total Bilirubin \>2xULN;Urea nitrogen:\>2.5xULN; Creatinine, serum\>1.5xbaseline assessment or change \>0.3mg/dL since last visit;Glucose,blood (non-fasting):\<55/\>160mg/dL;Calcium:\<7/\>11.5mg/dL;Total protein: \<5/\>9g/dL; Albumin:\<3g/dL;Sodium:\<130/\>150mmol/L;Potassium:\<3/\>5.5mmol/L; Uric acid,serum:\>10mg/dL Males,\>8mg/dL Females;Gamma Glutamyl Transpeptidase:\>2.5xULN; Phosphorus,inorganic:\<2.5/\>5mg/dL;Lactate dehydrogenase:\>3xULN;Urinalysis-Protein:\>20mg/dL.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Tests for IgPro10 | 0 | 0 |
Clinically significant abnormality criteria for vital signs included Systolic blood pressure (BP): \<100 millimeters of mercury (mmHg) or ≥140 mmHg or ≥140 mmHg and increase \>10 from reference visit; Diastolic BP: \<50 mmHg or ≥90 mmHg or ≥90 mmHg and increase \>10 from reference visit; Pulse rate: \<50 beats/minute or ≥120 beats/minute or ≥120 beats/minute and increase \>15 from reference visit; Weight (kilograms) ≥10% change (increase and decrease) from baseline assessment; Body temperature: \> 39-degree Celsius (°C ) or \<35°C (oral, tympanic, axilla or forehead).
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs for IgPro10 | 0 | 0 |
Clinically significant abnormality criteria for ECG parameters included Heart rate: ≤50 or ≥100 beats/minute; PR Interval: ≥200 millisecond (msec); QRS Interval: ≥120 msec; QT: ≥480 msec; QT interval corrected using Bazett' s formula (QTcB): ≤ 500 msec; QT interval corrected using Fridericia's formula (QTcF): \>500 msec; QT: increase from baseline ≥ 30; QTcB: increase from baseline \< 60 msec; QTcF: increase from baseline ≥ 60.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in ECG Parameters for IgPro10 | 0 | 0 |
PFTs include Spirometry which included forced vital capacity (FVC) % Predicted, considered as clinically significant abnormality when decrease is greater than10 percentage points from the reference visit.
| Participants | Sequence A: IgPro10 | Sequence B: IgPro10 |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in PFTs for IgPro10 | 0 | 0 |
Results for this outcome have not been posted.
Collected over From first dose of study drug through last follow up visit (up to 36 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sequence A: IgPro20 | 0/13 (0%) | 2/13 (15.4%) | 8/13 (61.5%) |
| Sequence A: IgPro10 | 0/13 (0%) | 1/13 (7.7%) | 5/13 (38.5%) |
| Sequence B: IgPro10 | 0/14 (0%) | 1/14 (7.1%) | 8/14 (57.1%) |
| Sequence B: IgPro20 | 0/13 (0%) | 3/13 (23.1%) | 6/13 (46.2%) |
| Event | Sequence A: IgPro20 | Sequence A: IgPro10 | Sequence B: IgPro10 | Sequence B: IgPro20 |
|---|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/13 | 0/13 | 0/14 | 0/13 |
| Chest painGeneral disorders | 1/13 | 0/13 | 0/14 | 0/13 |
| Chronic gastritisGastrointestinal disorders | 0/13 | 1/13 | 0/14 | 0/13 |
| VomitingGastrointestinal disorders | 0/13 | 1/13 | 0/14 | 0/13 |
| DehydrationMetabolism and nutrition disorders | 0/13 | 1/13 | 0/14 | 0/13 |
| Myocardial infarctionCardiac disorders | 0/13 | 0/13 | 0/14 | 1/13 |
| Myocardial ischaemiaCardiac disorders | 0/13 | 0/13 | 0/14 | 1/13 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/13 | 0/14 | 1/13 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/13 | 0/13 | 0/14 | 1/13 |
| Viral InfectionInfections and infestations | 0/13 | 0/13 | 1/14 | 0/13 |
| Event | Sequence A: IgPro20 | Sequence A: IgPro10 | Sequence B: IgPro10 | Sequence B: IgPro20 |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/13 | 0/13 | 5/14 | 0/13 |
| Abdominal painGastrointestinal disorders | 2/13 | 0/13 | 0/14 | 0/13 |
| Infusion site swellingGeneral disorders | 0/13 | 0/13 | 0/14 | 2/13 |
| COVID-19Infections and infestations | 1/13 | 0/13 | 0/14 | 2/13 |
| DiarrhoeaGastrointestinal disorders | 1/13 | 0/13 | 2/14 | 0/13 |
| NauseaGastrointestinal disorders | 0/13 | 0/13 | 2/14 | 1/13 |
| ErythemaSkin and subcutaneous tissue disorders | 0/13 | 0/13 | 2/14 | 0/13 |
| ToothacheGastrointestinal disorders | 0/13 | 1/13 | 0/14 | 1/13 |
| VomitingGastrointestinal disorders | 0/13 | 0/13 | 1/14 | 1/13 |
| Abdominal distensionGastrointestinal disorders | 1/13 | 0/13 | 0/14 | 0/13 |
Safety analysis set included all participants who received at least 1 infusion of IgPro20 or IgPro10.
| Age, Continuous(years) | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) | Total |
|---|---|---|---|
| Mean | 51.4 ± 12.22 | 47.4 ± 12.91 | 49.3 ± 12.50 |
| Sex: Female, Male(Participants) | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) | Total |
|---|---|---|---|
| Female | 10 | 8 | 18 |
| Male | 3 | 6 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 14 | 26 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) | Total |
|---|---|---|---|
| Race — White | 13 | 13 | 26 |
| Race — Other | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Sequence A (IgPro20/IgPro10) | Sequence B (IgPro10/IgPro20) | Total |
|---|---|---|---|
| Poland | 9 | 8 | 17 |
| United Kingdom | 3 | 3 | 6 |
| Italy | 1 | 0 | 1 |
| Australia | 0 | 2 | 2 |
| Germany | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Ran from Sep 2019 to primary completion in May 2022, 31 months.
Results were first posted in Feb 2024, 1 year 8 months after primary completion.
Of 24 phase 2 interventional studies under Scleroderma, Diffuse, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 108. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hizentra · IGPRO10